Form 4: Baker Bros. Boosts MDGL Stake

Baker Bros. Advisors and related entities significantly increased their indirect beneficial ownership in Madrigal Pharmaceuticals common stock through multiple purchases.

Summary

• Baker Bros. Advisors LP and related entities, including 667, L.P. and Baker Brothers Life Sciences LP, acquired additional common stock of Madrigal Pharmaceuticals, Inc. (MDGL).
• Transactions occurred on August 18, 2025, involving multiple purchases at weighted average prices ranging from $353.76 to $372.50 per share.
• Following these transactions, indirect beneficial ownership for one set of holdings increased to 194,625 shares, and for another set, to 1,859,091 shares.
• Julian C. Baker and Dr. Raymond Cheong, directors of Madrigal Pharmaceuticals, are associated with the reporting entities.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
• The filing notes that 3,825 shares of common stock were received from vested restricted stock units (RSUs) previously granted to Julian C. Baker and Dr. Raymond Cheong as directors.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to substantial insider buying by a major institutional investor and 10% owner, Baker Bros. Advisors, and its affiliates. This indicates strong confidence in Madrigal Pharmaceuticals' future performance and strategic direction.

Positives

• Significant insider buying by Baker Bros. Advisors and related entities, indicating strong confidence in Madrigal Pharmaceuticals' future prospects.
• The acquisitions were made at various price points, suggesting a strategic accumulation of shares.
• The increase in indirect beneficial ownership by a major institutional investor and 10% owner signals a positive long-term view.

Risks

• The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest, which could imply complex ownership structures.
• The prices reported are weighted averages, meaning shares were traded at a range of prices, which introduces slight variability.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance, focusing solely on past insider transactions.

Management Comments

• Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC, and Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP, are directors of Madrigal Pharmaceuticals, Inc.
• By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Julian C. Baker are deemed directors by deputization of the Issuer.
• The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the 'Staff'), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

Industry Context

This insider buying activity by a prominent biotech investor group like Baker Bros. Advisors suggests continued confidence in the pharmaceutical sector, particularly in companies like Madrigal Pharmaceuticals, which may be advancing key drug candidates or showing strong market potential.

Corporate Governance

Related Party Transactions

• Acquisition of common stock by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker, Julian C. Baker, 667, L.P., and Baker Brothers Life Sciences LP, all of whom are related parties (directors, 10% owners, or entities controlled by them) to Madrigal Pharmaceuticals, Inc.
• Receipt of 3,825 shares from vested restricted stock units by Julian C. Baker and Dr. Raymond Cheong, directors of the Issuer, with the pecuniary interest flowing to the Funds.

Stakeholder Impact

• Shareholders: The significant insider buying by a major institutional investor could be seen as a positive signal, potentially increasing investor confidence and demand for the stock.
• Management: Reinforces alignment between the interests of key investors/directors and the company's performance.

Next Steps

• Madrigal Pharmaceuticals' ongoing corporate developments and clinical trial progress.
• Future SEC filings by Baker Bros. Advisors regarding their holdings in Madrigal Pharmaceuticals.

Key Dates

Recommendation

The substantial insider buying by Baker Bros. Advisors, a highly respected and knowledgeable institutional investor with significant stakes and board representation in Madrigal Pharmaceuticals, signals strong conviction in the company's future. Such large-scale purchases by insiders, especially a 10% owner and director, are often interpreted as a very positive indicator of anticipated growth or undervaluation, making it a compelling 'strong buy' signal for seasoned investors.

Keywords

Madrigal Pharmaceuticals, MDGL, Baker Bros. Advisors, Insider Buying, Stock Acquisition, SEC Form 4, Biotechnology, Pharmaceuticals, Institutional Investor, Beneficial Ownership